Dengue virus (DV) is responsible for ~390 million infections annually, which can lead to dengue fever or the potentially lethal dengue hemorrhagic fever or shock syndrome. Four serotypes of DV exist (DV1-DV4), and infection by one serotype confers long-lasting immunity only to that particular serotype. Currently, there are no therapies against DV infection approved by the US Food and Drug Administration. A tetravalent vaccine candidate has completed two phase III clinical trials but has shown weak to moderate protection against DV serotype 2 (DV2) 1,2 . Hence, there is a pressing need for better understanding of dengue pathogenesis to aid in the design of broadly effective vaccines and antiviral agents.
Dengue virus (DV) is responsible for ~390 million infections annually, which can lead to dengue fever or the potentially lethal dengue hemorrhagic fever or shock syndrome. Four serotypes of DV exist (DV1-DV4), and infection by one serotype confers long-lasting immunity only to that particular serotype. Currently, there are no therapies against DV infection approved by the US Food and Drug Administration. A tetravalent vaccine candidate has completed two phase III clinical trials but has shown weak to moderate protection against DV serotype 2 (DV2) 1, 2 . Hence, there is a pressing need for better understanding of dengue pathogenesis to aid in the design of broadly effective vaccines and antiviral agents.
Germline-encoded pattern-recognition receptors are key components of the innate immune system. They detect microbial nucleic acids or structural components and subsequently trigger an antiviral response 3, 4 . Among these, RIG-I has emerged as a key sensor of many RNA viruses, including DV, that acts by recognizing cytosolic viral RNA species harboring a 5′ tri-or di-phosphate moiety and/or poly(U-UC) motifs 5, 6 . The binding of viral RNA triggers a conformational change in RIG-I that allows Lys63 (K63)-linked ubiquitination at its N-terminal caspase-activation-and-recruitment domains (2CARD) mediated by the E3 ubiquitin ligase TRIM25 (refs. 7-9) . Ubiquitination of RIG-I facilitates its tetramerization, and the activated RIG-I tetramer subsequently translocates from the cytosol to the adaptor MAVS, present at the outer mitochondrial membrane, mitochondria-associated membranes and peroxisomes [10] [11] [12] . MAVS assembles a multi-protein signaling complex that leads to activation of the transcription factor IRF3 or IRF7 to induce the expression of type I interferons, proinflammatory cytokines and interferon-stimulated genes (ISGs) 13, 14 . The mitochondria-targeting chaperone 14-3-3ε has been identified as a crucial mediator of the redistribution of RIG-I from the cytosol to mitochondrion-associated MAVS that acts by forming a 'translocon' complex with RIG-I and TRIM25, ultimately triggering an antiviral response 15 .
DV has evolved to evade both innate immune responses and adaptive immune responses, which allows it to replicate unchecked and to disseminate 16 . DV suppresses both the induction of type I interferons and signal transduction via the receptor for interferon-α (IFN-α) or IFN-β through a variety of strategies 17 . Specifically, the DV nonstructural protein NS5 blocks signaling via the receptor for IFN-α and IFN-β by inducing degradation of the transcription factor STAT2 (ref. 18) , while the DV protease complex consisting of the nonstructural protein NS3 together with its cofactor NS2B cleaves STING 19, 20 , an adaptor downstream of cytosolic DNA sensors. However, how DV escapes innate immunological detection by RIG-I is unknown. Here we found that DV NS3 bound to 14-3-3ε through the use of a highly conserved phosphomimetic motif and blocked the translocation of RIG-I to mitochondria and, thus, antiviral signaling. A recombinant DV encoding a mutant NS3 protein deficient in binding to 14-3-3ε lost the ability to antagonize RIG-I and elicited an augmented innate immune response and enhanced T cell activation.
RESULTS

Interaction of NS3 with 14-3-3
We hypothesized that NS3 and NS5, two major interferonantagonistic proteins of DV, would inhibit innate host defense via unidentified mechanisms. To address this, we sought to identify previously unknown cellular interaction partners of NS3 and NS5 by affinity purification and mass-spectrometry analysis of FLAG-tagged defined domains of both viral proteins: the NS3 protease and helicase domains (FLAG-NS3-Pro and FLAG-NS3-Hel, respectively), as well as the NS5 methyltransferase and polymerase domains (FLAG-NS5-MTase and FLAG-NS5-Pol, respectively). The mass-spectrometry A r t i c l e s analysis showed that 14-3-3ε was present specifically in complex with FLAG-NS3-Pro but not with the other domains ( Supplementary  Fig. 1a and data not shown).
We first confirmed that c-Myc-tagged 14-3-3ε bound specifically to NS3-Pro but not to NS3-Hel (Fig. 1a) . In agreement with our massspectrometry results, FLAG-14-3-3ε interacted specifically with NS3 fused to glutathione S-transferase (GST-NS3) but not with GST-NS5 or GST alone (Fig. 1b) . Furthermore, GST-NS3 interacted specifically with 14-3-3ε but not with 14-3-3σ, which shares ~75% homology with 14-3-3ε (Fig. 1c) . Moreover, exogenously expressed NS3 of DV interacted strongly with 14-3-3ε, whereas the NS3 proteins of hepatitis C virus (HCV) and yellow fever virus (YFV), also members of the family Flaviviridae, did not bind 14-3-3ε (Fig. 1d) . Notably, NS3 efficiently formed a complex with endogenous 14-3-3ε during DV infection (Fig. 1e) . Confocal microscopy showed that 14-3-3ε was expressed throughout the cytoplasm, whereas DV NS3, as previously reported, formed perinuclear cytoplasmic speckles, indicative of DV-replication complexes 21 , at ER-derived membranes (Fig. 1f) . NS3 partially co-localized with 14-3-3ε in these perinuclear bodies, which also costained for NS4A, a key component of the DV replication complex 22 ( Fig. 1f and Supplementary Fig. 1b) . Finally, GST-NS3 immobilized on agarose beads efficiently bound to bacterially purified recombinant 14-3-3ε, but GST did not (Fig. 1g) ; this demonstrated a direct interaction. These results indicated that NS3 and 14-3-3ε bound directly to each other and formed a complex during infection with DV.
Control of DV replication by 14-3-3 14-3-3ε mediates the redistribution of RIG-I from the cytosol to mitochondria for interaction with MAVS and antiviral signaling. Infection studies have demonstrated that 14-3-3ε is required for an effective antiviral response to Sendai virus (SeV), vesicular stomatitis virus and HCV, all of which are sensed by RIG-I 15 . We found that ectopically expressed 14-3-3ε also suppressed the replication of DV strains representing all four serotypes (DV1-DV4) but had no effect on herpes simplex virus type 1 (HSV-1), a DNA virus ( Supplementary Fig. 1c-e) . Cells in which 14-3-3ε was ectopically expressed showed enhanced activation of an interferon-sensitive response element-containing promoter upon DV infection (Supplementary Fig. 1f ), which indicated a role for the interferon response in 14-3-3ε-mediated control of DV replication. When we depleted Huh7 human hepatocyte-derived cellular carcinoma cells of 14-3-3ε through the use of small interfering RNA (siRNA), we observed cytotoxic effects (data not shown), which precluded assessment of DV replication. However, studies of K562 human myeloid cells, which tolerated depletion of 14-3-3ε better, showed that knockdown of 14-3-3ε markedly enhanced DV replication compared with its replication in cells treated with non-targeting control siRNA (Supplementary Fig. 1g) , which supported the conclusion of a role for 14-3-3ε in controlling DV replication.
Proteolysis-independent inhibition of RIG-I by NS2B-NS3 NS3 together with its cofactor NS2B forms the DV protease complex, and it is believed that for most flaviviruses, the proteolytic activity of the viral protease is essential for antagonizing host immunity. For example, DV NS2B-NS3 has been shown to cleave STING 19, 20 , while NS3-NS4A of HCV cleaves MAVS 23, 24 . Therefore, we first sought to determine whether NS3 in complex with NS2B was able to cleave 14-3-3ε. Overexpression of wild-type NS2B-NS3 (NS2B-NS3(WT)) did not result in any cleavage products of co-expressed 14-3-3ε ( Supplementary Fig. 2a and data not shown). In accord, the amount of endogenous 14-3-3ε protein was unchanged during DV infection (Fig. 1e) , which suggested that DV NS2B-NS3 did not cleave 14-3-3ε. NS2B-NS3 did not cleave TRIM25 or RIG-I either, but readily cleaved STING (Supplementary Fig. 2a) . We also generated a catalytically inactive mutant of NS2B-NS3 (NS2B-NS3(S135A)) 25 that, in contrast to NS2B-NS3(WT), was unable to cleave itself or STING (Supplementary Fig. 2b ). Both NS2B-NS3(WT) and NS2B-NS3(S135A) potently suppressed the activation of the promoter of the gene encoding IFN-β (IFNB1) mediated by RIG-I 2CARD, the constitutively active signaling module of RIG-I (Fig. 2a,b) . In contrast, wild-type HCV NS3-NS4A (NS3-NS4A(WT)) suppressed the RIG-I 2CARD-mediated induction of IFN-β, but the catalytically inactive mutant NS3-NS4A(S139A) did not (Fig. 2a) . Notably, NS3 alone, which has no proteolytic activity 26 ( Supplementary  Fig. 2b ), blocked the RIG-I 2CARD-or SeV-induced activation of the IFNB1 promoter as potently as NS2B-NS3(WT) and NS2B-NS3(S135A) did (Fig. 2b,c) . Overexpression of NS3 also markedly inhibited IRF3 dimerization and ISG induction triggered by SeV infection (Fig. 2d,e) . Crucially, ectopic expression of NS3 did not inhibit SeV infection (Supplementary Fig. 2c ), which ruled out the possibility that the dampening effect of NS3 on RIG-I signaling was due to lessefficient SeV replication. Furthermore, NS3 suppressed activation of the IFNB1 promoter mediated by RIG-I 2CARD, but not that mediated by MAVS (Fig. 2f) , which further supported the proposal that NS3 acted at the level of RIG-I. These results indicated that DV NS3 inhibited RIG-I-and 14-3-3ε-mediated signaling in a cleavageindependent manner.
Prevention of RIG-I-14-3-3 binding by NS3
To gain further insight into the mechanism by which RIG-I is antagonized, we sought to determine whether NS3 blocked the K63-linked ubiquitination of RIG-I, interfered with formation of the 14-3-3ε-RIG-I-TRIM25 complex or inhibited the translocation of RIG-I to mitochondria, all of which are critical steps in the activation of RIG-I. Efficient ubiquitination of FLAG-tagged RIG-I after infection with SeV was detected in cells also expressing either GST or GST-NS3 (Fig. 3a) . Consistent with that, we detected robust ubiquitination of endogenous RIG-I during infection with DV ( Fig. 3b) , which indicated that DV did not inhibit the K63-linked ubiquitination of RIG-I. We found that infection with SeV robustly triggered the binding of both 14-3-3ε and TRIM25 to RIG-I; however, expression of GST-NS3 profoundly diminished the binding of RIG-I to 14-3-3ε but not to TRIM25, and expression of GST did neither (Fig. 3c) . In agreement with that, infection with DV induced endogenous formation of the RIG-I-TRIM25 complex as efficiently as did infection with SeV ( Fig. 3d) . However, the interaction between 14-3-3ε and RIG-I during DV infection was minimal and comparable to that of mock-infected cells (Fig. 3d) . This indicated that NS3 did not affect the binding of TRIM25 to RIG-I or the K63-linked ubiquitination of RIG-I but instead specifically blocked the RIG-I-14-3-3ε interaction. In agreement with that, RIG-I interacted with recombinant 14-3-3ε in vitro, but TRIM25 did not ( Supplementary Fig. 3a) , which suggested that the RIG-I-14-3-3ε interaction was direct, whereas TRIM25 bound Fig. 3b ).
A competitive binding assay showed that NS3 inhibited the RIG-I-14-3-3ε interaction in a dose-dependent manner (Fig. 3e) . Fractionation studies showed that RIG-I failed to translocate to the mitochondrial fraction during DV infection and was present almost exclusively in the cytosolic fraction, similar to results obtained for mock-infected cells (Fig. 3f) . In contrast, in SeV-infected cells, RIG-I was abundant in the mitochondrial fraction, along with MAVS ( Fig. 3f) , indicative of its translocation. Furthermore, ectopic expression of GST-NS3 diminished the amount of RIG-I in the mitochondrial fraction of SeV-infected cells (Supplementary Fig. 3c ). Overexpression of 14-3-3ε restored the cytosol-to-mitochondria translocation of RIG-I during DV infection (Supplementary Fig. 3d ), in support of the proposal that the defect in RIG-I translocation in DV-infected cells was due to antagonism of 14-3-3ε. These data indicated that NS3 blocked 14-3-3ε from interacting with the activated RIG-I-TRIM25 complex, which prevented RIG-I from translocating to mitochondria to initiate signaling.
Binding of NS3 to 14-3-3 via a phosphomimetic motif To identify the binding site of 14-3-3ε in NS3-Pro, we constructed truncation fragments of NS3-Pro. We then assessed their ability to bind endogenous 14-3-3ε by co-immunoprecipitation. Full-length GST-NS3 and GST-tagged truncation fragments consisting of amino acids 1-92 or 43-92 of NS3 efficiently interacted with 14-3-3ε, but other NS3 fragments did not ( Fig. 4a and Supplementary Fig. 4a ).
A hallmark of many cellular proteins that bind to members of the 14-3-3 family is the presence of a canonical high-affinity binding motif, Rxx(pS/pT)xP (where 'x' indicates any residue and 'pS/pT' indicates a phosphorylated serine or threonine residue) 27 . Phosphorylation of serine or threonine in Rxx(pS/pT)xP is essential for binding to 14-3-3 proteins, as dephosphorylation of this residue abolishes the 14-3-3 interaction 28 . Closer examination of the NS3 truncation fragment consisting of amino acids 43-92, which was sufficient for binding to 14-3-3ε (Fig. 4a) , revealed a 'compact' motif, Arg64-X65-Glu66-Pro67 ('64-RxEP-67'), that resembled the cellular motif but had a charged residue (Glu66) in place of the phosphorylated serine or threonine residue (Fig. 4b) . On the basis of the crystal structure of DV NS3 protein 29 , the 64-RxEP-67 motif is exposed and is present on a surface distal to the catalytic site ( Fig. 4c and Supplementary Fig. 4b ). The DV2 strains NGC and 16681 harbor an Arg64-Ile65-Glu66-Pro67 ('64-RIEP-67') motif, while DV1, DV3 and DV4 have a similar motif, Arg64-Leu65-Glu66-Pro67 ('64-RLEP-67') ( Fig. 4b) , which would suggest that the 64-RxEP-67 motif is conserved across DV strains. Indeed, bioinformatics analysis aligning more than 3,000 NS3 sequences derived from fully sequenced strains DV1-DV4 showed that the 64-RxEP-67 motif was conserved in all NS3 sequences analyzed except two (one polymorphism each for Glu66 and Pro67 in the RxEP motif was identified), while adjacent residues showed substantially more polymorphisms (Fig. 4d) .
Since glutamic acid is a negatively charged residue that is often used to mimic phosphorylated serine or threonine in molecular biology experiments, we hypothesized that DV NS3 might utilize the phosphomimetic Glu66 in 64-RxEP-67 for binding to 14-3-3ε. To test this hypothesis, we introduced the corresponding motif from DV1, DV3 and DV4 (Arg64-Leu65-Glu66-Pro67 (RLEP)) or WNV (Arg64-Leu65-Asp66-Pro67 (RLDP)), each of which has a phosphomimetic residue (Glu66 or Asp66), into full-length NS3 derived from DV2 (strain NGC, which contains the motif RIEP). We also introduced the corresponding motif from YFV (Lys64-Leu65-Ile66-Pro67 (KLIP)), which has an uncharged hydrophobic residue at position 66 (Ile66), into DV2 NS3. Chimeric NS3 proteins containing RLEP or RLDP, and thus Glu66 or Asp66, were able to bind 14-3-3ε, while the chimeric NS3 protein containing KLIP (Ile66) showed considerably diminished binding to 14-3-3ε (Supplementary Fig. 4c ). This suggested that Asp66, which is also a phosphomimetic residue, was able to substitute for Glu66, and that Ile65 and Leu65 were functionally equivalent.
To confirm the importance of the phosphomimetic Glu66 in DV NS3 for binding to 14-3-3ε, we replaced the glutamic acid at position 66 with aspartic acid (an acidic residue similar to Glu; Asp66), glutamine (side chain similar to that of glutamic acid, but uncharged; Gln66), or lysine (positively charged residue; Lys66). Whereas substitution of Glu66 with Asp66 did not affect the binding of NS3 to 14-3-3ε, the introduction of Gln66 or Lys66 diminished its binding to 14-3-3ε (Fig. 4e) , which further strengthened the conclusion that the phosphomimetic Glu66 (or Asp66) was critical for this interaction with 14-3-3ε. Furthermore, additional substitution of Arg64 with Lys64 (NS3(KIKP)) led to a nearly complete loss of binding to 14-3-3ε (Fig. 4e) , which demonstrated the importance of Glu66 and Arg64 for the interaction of NS3 with 14-3-3ε. Interestingly, introduction of the 64-RxEP-67 motif into the NS3 protein of YFV, which was unable to bind 14-3-3ε (Fig. 1d) , did not allow the binding of YFV NS3 to 14-3-3ε (data not shown), which suggested that additional residues beyond the 64-RxEP-67 motif or the overall conformation of NS3 were important for its binding to 14-3-3ε. Collectively, these results indicated that DV NS3 bound to 14-3-3ε via a compact RxEP motif with a phosphomimetic (Glu66) residue.
Functional studies showed that whereas NS3(WT) potently inhibited the SeV-induced binding of RIG-I to 14-3-3ε, NS3(KIKP) did not affect their interaction (Supplementary Fig. 4d) . Consistent with that, NS3(WT) potently blocked the translocation of RIG-I to mitochondria, but NS3(KIKP) did not (Fig. 4f) . Furthermore, expression of NS3(WT) markedly suppressed the SeV-mediated transcriptional activation of IFNB1 and expression of proteins encoded by ISGs, but expression of NS3(KIKP) did not ( Supplementary Fig. 4e,f) . This showed that a mutant DV NS3 protein deficient in binding to 14-3-3ε was unable to inhibit the cytosol-to-mitochondria translocation of RIG-I or to suppress antiviral gene expression.
Phosphomimetic RLDP motif in WNV NS3
As WNV NS3 has a motif (Arg64-Leu65-Asp66-Pro67 ('64-RLDP-67')) similar to that in DV NS3, in which Asp66 might act as a phosphomimetic for binding to 14-3-3ε, we first assessed the ability of NS3 from two different WNV strains (NY99 and Kunjin) to interact with 14-3-3ε. WNV NS3 efficiently bound to endogenous 14-3-3ε ( Supplementary  Fig. 5a ). In line with that, ectopic expression of WNV NS3 robustly inhibited RIG-I 2CARD-mediated activation of the IFNB1 promoter (Supplementary Fig. 5b) . Furthermore, as seen with DV NS3, substitution of the 64-RLDP-67 motif in WNV NS3 with 64-KIKP-67 (Lys64-Ile65-Lys66-Pro67) substantially diminished its interaction with 14-3-3ε (Supplementary Fig. 5c ). Our results indicated that the NS3 protein of both DV and WNV targeted 14-3-3ε to inhibit RIG-I signaling and further reinforced the proposal of the importance of a phosphomimetic motif in the viral NS3 protein for its binding to 14-3-3ε. 
A r t i c l e s
Innate immune response elicited by DV2 NS3(KIKP)
To determine the physiological relevance of the disruption of 14-3-3ε-mediated translocation of RIG-I by NS3, we sought to construct a recombinant DV encoding NS3(KIKP). Because NS3, as part of the protease complex, processes the viral polyprotein and is therefore essential for the replication of DV, we first assessed whether NS2B-NS3(KIKP) retained its proteolytic activity. Similar to NS2B-NS3(WT), NS2B-NS3(KIKP) was able to cleave itself and STING (Supplementary Fig. 6a) . Using reverse genetics, we introduced the R64K and E66K substitutions in an infectious clone originally derived from the DV2 16681 strain 30, 31 and thus engineered a recombinant mutant DV encoding NS3(KIKP) (called 'DV2(KIKP)' here). DV2(KIKP) exhibited a slightly reduced (approximately one-log) replication capacity compared with that of the parental virus (wildtype DV2 (DV2(WT)) in Vero African green monkey kidney cells, which are deficient in type I interferon responses 32 ( Supplementary  Fig. 6b,c) ; this suggested that DV2(KIKP) was slightly attenuated independently of type I interferons. In Huh7 cells, which have an intact type I interferon response, DV2(WT) and DV2(KIKP) exhibited similar replication at 24 h after infection ( Supplementary  Fig. 6d) ; however, at 72 h after infection, the replication of DV2(KIKP) was strongly suppressed, while DV2(WT) replicated efficiently (Fig. 5a) . In contrast, DV2(KIKP) replicated almost as efficiently as DV2(WT) in Huh7.5 cells, a sub-line of Huh7 cells that naturally expresses a mutant RIG-I protein that is defective in binding to TRIM25 and, thus, activation of RIG-I 33, 34 (Fig. 5a) .
DV2(KIKP) induced larger amounts of IFNB1 transcripts than did DV2(WT), especially at late time points after infection (Fig. 5b) . DV2(KIKP) also elicited greater production of IFN-β protein than did DV2(WT) or vesicular stomatitis virus, but did so less efficiently than Newcastle disease virus (NDV), which is known to robustly induce the production of IFN-β (Supplementary Fig. 6e) . Crucially, the enhanced interferon-inducing ability of DV2(KIKP) was not due to larger amounts of viral RNA (Supplementary Fig. 6f ). DV2(KIKP) also elicited significantly larger amounts of transcripts from ISGs and genes encoding proinflammatory cytokines and chemokines than did DV2(WT) (Fig. 5c) . In agreement with that, DV2(KIKP) robustly induced the expression of ISG-encoded proteins in neighboring uninfected cells, but DV2(WT) did not (Supplementary Fig. 6g ). To determine if the greater induction of IFN-β by DV2(KIKP) was indeed mediated by RIG-I, we compared the abundance of IFNB1 transcripts in Huh7 and Huh7.5 cells following infection with DV2(WT) or DV2(KIKP). DV2(WT) triggered low induction of IFNB1 in both cells; in contrast, DV2(KIKP) strongly induced IFNB1 expression in Huh7 cells but not in Huh7.5 cells, similar to infection with SeV, a virus sensed specifically by RIG-I (Fig. 5d) . Depletion of RIG-I also substantially diminished the induction of IFNB1 triggered by DV2(KIKP) (Fig. 5e) , which further strengthened the proposal that DV2(KIKP) induced innate signaling in a RIG-I-dependent manner. Notably, we verified that DV2(WT) and DV2(KIKP) were both able to effectively degrade STAT2 (Supplementary Fig. 6h) . Mechanistically, DV2(KIKP) efficiently induced the translocation of RIG-I to mitochondria, but DV2(WT) did not (Fig. 5f) . Collectively, these results indicated that DV2(KIKP) failed to antagonize RIG-I and thus elicited enhanced induction of cytokine-encoding genes and ISGs.
Activation of immune cells by DV2(KIKP)
Although the liver is commonly involved in DV infection, mononuclear phagocytes are thought to be the main in vivo cell targets for DV replication 35 . IFNB1 transcripts in primary human CD14 + monocytes npg were below the detection limit after infection with either DV2(WT) or DV2(KIKP) (data not shown). However, we detected robust expression of genes encoding proinflammatory cytokines and secretion of interleukin 6 (IL-6) protein after infection with DV2(KIKP) but not after infection with DV2(WT) (Fig. 6a,b) . The antagonism of type I interferons by DV contributes to the inefficient priming of T cells 36 . To determine if DV2(KIKP) elicited an enhanced T cell response compared with that elicited by DV2(WT), we first infected primary human monocyte-derived dendritic cells (moDCs) with DV2(WT) or DV2(KIKP). These viruses induced comparable expression of the costimulatory marker CD86 (Supplementary Fig. 6i ). However, in infected moDCs that had been cultured together with syngeneic naive 'pan' T cells (all subsets), DV2(KIKP) elicited a trend of a greater abundance of IFNB1 transcripts and significantly larger amounts of IL6 and IL8 mRNA relative to that elicited by DV2(WT) (Fig. 6c) . Furthermore, DV2(KIKP) triggered phosphorylation of STAT1 in primary T cells more efficiently than did DV2(WT) or NDV ( Fig. 6d and Supplementary Fig. 6j) , indicative of augmented activation of the receptor for IFN-α and IFN-β by DV2(KIKP). In accordance with that, co-cultures of T cells and DV2(KIKP)-infected moDCs secreted larger amounts of IFN-γ and tumor-necrosis factor than did co-cultures infected with DV2(WT) (Fig. 6e,f) . The production of tumor-necrosis factor induced by DV2(KIKP), however, was more moderate than that induced by NDV (Fig. 6f) . Together, these results indicated that DV2(KIKP) efficiently triggered innate immune responses in human hepatocytes and primary human mononuclear phagocytes, which in turn led to greater T cell activation.
DISCUSSION
Membrane-bound organelles serve important roles in the orchestration of antimicrobial immunity by acting as platforms for the assembly of multi-protein signaling complexes. Hence, upon recognition of pathogen-associated molecular patterns, cytosolic patternrecognition receptors must relocate from the sites at which the pathogen-associated molecular patterns are detected to such organelles, a highly regulated process that requires specific trafficking factors. However, it has remained unknown whether viral pathogens target specific trafficking proteins to perturb the translocation of pattern-recognition receptors. Our findings showed that whereas RIG-I was initially ubiquitinated and activated during DV infection, NS3 disrupted its interaction with 14-3-3ε, which blocked the translocation of RIG-I to mitochondrion-localized MAVS. Thus, unlike HCV NS3-NS4A, DV NS2B-NS3 inhibited RIG-I-mediated signaling in a cleavage-independent manner, which highlights the importance of proteolysis-independent functions of viral proteases in manipulation of the host response.
The chemical similarity of phosphomimetic residues (glutamic acid or aspartic acid) and phosphorylated serine or threonine is well established, which has led investigators to commonly utilize glutamic acid or aspartic acid to mimic site-specific phosphorylation in molecular biology experiments. Our mutational analysis showed that Glu66 in the 64-RxEP-67 motif of DV NS3 was critical for its binding to 14-3-3ε, which provides an example of a naturally occurring phosphomimetic used in an infectious-disease mechanism. Using a phosphomimetic residue for binding to 14-3-3ε might provide advantages to DV, such as the lack of requirement for a kinase, whether viral or cellular, and the uniform 'phosphorylation state' of all NS3 molecules. Interestingly, the synthetic peptide R18, which is commonly used to block the binding of 14-3-3 proteins to cellular proteins, also has a phosphomimetic motif (Trp-Leu-Asp-Leu-Glu (WLDLE)), in which aspartic acid and glutamic acid engage the same residues in 14-3-3 proteins that are engaged by the motifs of cellular proteins that contain phosphorylated serine or threonine 37 . Thus, in addition to canonical phosphorylated motifs, short phosphomimetic sequences, either synthetic or naturally occurring in a viral pathogen, mediate efficient binding to 14-3-3 proteins. Additional studies are needed to determine if DV NS3 also antagonizes other functions of 14-3-3ε or other members of the 14-3-3 family.
DV is known to potently suppress the innate immune system, a prerequisite for successful viral replication and pathogenesis. Our studies of a mutant DV deficient in binding to 14-3-3ε and antagonism of RIG-I showed that disabling a specific viral interferon-antagonistic mechanism led to attenuation of viral growth and efficient activation of innate and adaptive immunity. We propose that systematically disabling mechanisms for evasion of the immune system while preserving npg viral functions might allow the rational design of live attenuated vaccines against DV. Furthermore, our detailed characterization of the NS3-14-3-3ε interaction might also guide the design of smallmolecule inhibitors for antiviral therapy. In summary, our work has unveiled a key mechanism used by DV for evasion of the immune system, which might provide a framework for rational vaccine design and antiviral development.
METHODS
Methods and any associated references are available in the online version of the paper. Direct protein-interaction assay. Bacterially purified recombinant human 14-3-3ε protein (NP_006752.1) was purchased from Sino Biological. GST or GST-NS3 (DV2, strain NGC), expressed in HEK293T cells, was immobilized on glutathione-conjugated sepharose beads (G3907, Sigma) in NP-40 buffer and incubated with recombinant 14-3-3ε protein (final concentration of 10 µg/ml) for 2 h at 4 °C. After extensive washing with NP-40 buffer, bound proteins were eluted from the beads with 2× Laemmli buffer and heated at 95 °C for 5 min, followed by SDS-PAGE and immunoblot analysis. Similarly, TRIM25-FLAG and RIG-I-FLAG were purified from transfected HEK293T cells using anti-FLAG-conjugated sepharose beads (M2, Sigma) and tested for binding to recombinant 14-3-3ε.
Cytosol-mitochondria fractionation assay. HEK293T or Huh7 cells were infected with DV or SeV at indicated titers, or mock infected. Importantly, conditions were chosen for these fractionation assays in which the upregulation of endogenous RIG-I protein amounts by the different stimuli tested was minimal, allowing direct assessment of RIG-I translocation. 20-24 h later, a portion of cells was harvested for whole-cell lysates, and another portion for fractionation assay using a commercial mitochondria/cytosol fractionation kit (MIT1000, Merck Millipore) according to the manufacturer's instructions. Briefly, cells were disrupted in Isotonic Mitochondrial Buffer using a Dounce homogenizer. Lysates were subjected to low-speed centrifugation to pellet nuclei and unbroken cells. Supernatant was subsequently centrifuged at 10,000 × g for 30 min at 4 °C. The supernatant containing the cytosol and microsome fraction ('cytosolic fraction') as well as the pellet containing the enriched mitochondrial fraction were subjected to a bicinchoninic acid (BCA) assay. Equal amounts of protein were loaded for SDS-PAGE and analyzed by immunoblot. Anti-GAPDH and anti-MAVS immunoblot analyses served as controls.
DV infection and flow cytometry analysis. Infection was performed based on a published protocol 44 . Briefly, ~1.5 × 10 5 cells per well were seeded into 24-well plates and allowed to adhere for 4 h. Virus diluted in 250 µl DMEM containing 2% FBS was incubated with the cells at 37 °C for 1.5 h. At the indicated time points after infection, cells and/or supernatants were harvested. For K562 suspension cells, the infection was performed similarly except growth media was directly added to cells after infection. To detect DV-infected cells, cells were washed once in PBS, fixed in 1% (wt/vol) paraformaldehyde, permeabilized with 100 µl 0.1% saponin (Sigma), and then stained with antiprM-DyLight 633 in 50 µl permeabilization buffer for ~40 min at 4 °C. Subsequently, cells were washed with PBS and resuspended in 1% (wt/vol) paraformaldehyde before flow cytometry analysis on a FACSCalibur (BD Biosciences). Analysis was performed using FlowJo software (Tree Star). For Supplementary  Figure 1b -e, Huh7 cells were pre-transfected in 6-well plates for 48 h with 2.5 µg plasmid before re-seeding into 24-well plates for infection. Plaque assay using BHK-21 cells was performed as previously described 39 .
Bioinformatics analysis. NS3 protein sequences from full genome DV sequences were analyzed with NIAID Virus Pathogen Database and Analysis Resource (ViPR) online through the website at http://www.viprbrc.org.
Quantitative real-time PCR (qRT-PCR).
Total RNA was extracted from cells using an RNA extraction kit (OMEGA Bio-Tek). Equal amounts of RNA (typically 10-100 ng) were used in an one-step qRT-PCR reaction (SuperScript III Platinum One-Step qRT-PCR kit with ROX, Life Technologies) with commercially available primers with FAM reporter dye for the indicated target genes (IDT). Expression level for each target gene was calculated by normalizing against 18S (for dendritic cells) or GAPDH (all other cells) using the ∆∆CT method and expressed as fold levels compared to mock-infected cells. For viral genomic RNA (gRNA), custom primers were designed against a region in NS4A (forward primer: AACAGAGAACACCCCAAGAC; reverse primer: ATGCTTCCCAATCCGAGATC; probe: CCGCAACCATGGCAAACGAGAT), normalized to GAPDH, and expressed as fold levels compared to DV2(WT) infection. All qRT-PCR reactions were run on a 7300 RT-PCR System or 7500 FAST RT-PCR System (both ABI).
Generation of a mutant DV expressing NS3(KIKP). DV2(KIKP) was generated based on an infectious clone of DV2 16681, pD2/IC-30P, kindly provided by C. Huang (Center for Disease Control and Prevention) and described previously 30, 31 . PCR was used to generate mutant pD2/IC-30P harboring mutations encoding the substitutions R64K and E66K in the gene encoding NS3. The WT and mutant infectious clone plasmids were linearized by XbaI digestion and in vitro transcribed using the T7 promoter (RiboMAX Large Scale RNA Production System, Promega) with the addition of a m 7 G(5′)ppp(5′)A RNA cap structure analog (New England Biolabs). The in vitro transcribed RNA was purified using Micro Bio-Spin columns (Bio Rad) and transfected into Vero cells using Lipofectamine 2000. Viral supernatants were harvested and used to propagate the WT and mutant virus in Vero cells. Vero cells were further used to titer the recombinant viruses by serial dilution of the supernatant and staining with anti-prM (identified above), followed by flow cytometry 45 .
DV infection studies in primary human monocytes, moDCs and T cells.
Human peripheral blood or peripheral blood mononuclear cells (PBMCs) from unidentified healthy donors were purchased (HemaCare). This study was done in accordance with the ethical guidelines of Harvard Medical School. In the case of human peripheral blood, PBMCs were isolated using FicollHypaque (GE Healthcare) density gradient centrifugation. CD14 + monocytes were positively selected from PBMCs using anti-CD14 magnetic microbeads, and naive pan T cells were negatively selected from PBMCs with magnetic microbeads, according to the manufacturer's instructions (Miltenyi Biotec). The purity of CD14 + cells was routinely ~90%, as determined by anti-CD14-FITC staining (identified above; BD Biosciences) and flow cytometry analysis. For infection of monocytes, ~1.5 × 10 5 CD14 + monocytes per well were infected with DV2(WT) or DV2(KIKP) in a 96-well plate in 250 µl DMEM containing 2% FBS for 5 h, with occasional agitation. To obtain naive moDCs, CD14 + monocytes were cultured with 500 U/ml human GM-CSF and 1,000 U/ml human IL-4 (both purchased from Peprotech) for ~6 days. For infection of moDCs, ~1 × 10 5 naive moDCs per well were infected with DV2(WT), DV2(KIKP) or NDV at the indicated MOI values for 3 h in 96-well flat bottom plates. Subsequently, the media was replaced and ~1 × 10 5 syngeneic naive pan T cells were co-cultured with the moDCs (1:1 ratio). 72 h later, adherent moDCs were analyzed by qRT-PCR after rinsing off T cells with PBS three times, or T cells were analyzed for intracellular staining of phosphorylated STAT1. Furthermore, supernatants of moDC-T cell cocultures were analyzed for IFN-γ or TNF by ELISA (Biolegend or Affymetrix, respectively) 96 h after infection.
For intracellular staining of phosphorylated STAT1, T cells (~1 × 10 5 ) were fixed in 2% (wt/vol) paraformaldehyde, washed once with PBS, permeabilized with 100 µl Perm Buffer III (BD Biosciences) and then washed twice with PBS. Cells were blocked with 1 µg Human Fc block (BD Biosciences) in 25 µl PBS and subsequently stained with an Alexa Fluor 647-conjugated antibody to STAT1 phosphorylated at Tyr701 (identified above; BD Biosciences) by adding 5 µl of the antibody for 1 h at 4 °C. All flow cytometry data were acquired on a FACSCalibur (BD Biosciences) and analyzed using FlowJo (Tree Star) software.
Statistical analysis. Unpaired two-tailed Student's t-tests were used to compare differences between two unpaired experimental groups in all cases. A P value of <0.05 was considered statistically significant. No pre-specified effect size was assumed and in general three to five replicates for each condition was used, which was sufficient to demonstrate statistically significant differences. 
